Omberacetam

Template:Proofread Template:SubstanceBox/Noopept Noopept (GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1]

It is sold as a dietary supplement in the US and as a medication in other countries. Online however, noopept is freely available as a highly effective nootropic and stimulant which is effective at enhancing both cognition and productivity in a manner which is distinct but physically and mentally comfortable.

Chemistry

This chemistry section is incomplete. You can help by adding to it.

Pharmacology

Noopept is not a racetam (due to not having a 2-oxo-pyrrolidine skeleton),[2] but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system, as well as modulation of AMPA receptors.[3] When compared to traditional racetams, it has been found to be, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Noopept is a prodrug for the endogenous peptide cyclopropylglycine.

However, the role of these interactions and how they result in the compounds effects continues to remain elusive.